Opaleye Management as of June 30, 2016
Portfolio Holdings for Opaleye Management
Opaleye Management holds 49 positions in its portfolio as reported in the June 2016 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Auris Med Hldg | 9.7 | $15M | 2.1M | 6.88 | |
Nabriva Therapeutics | 7.2 | $11M | 2.0M | 5.55 | |
Amarin Corporation (AMRN) | 6.2 | $9.2M | 1.3M | 7.39 | |
Edge Therapeutics | 3.6 | $5.4M | 330k | 16.41 | |
Ophthotech | 3.5 | $5.2M | 8.2M | 0.64 | |
Biolinerx Ltd-spons | 3.4 | $5.1M | 250k | 20.25 | |
Inotek Pharmaceuticals Corp conv | 3.2 | $4.8M | 645k | 7.44 | |
Immunomedics | 3.2 | $4.8M | 1.3M | 3.76 | |
Chimerix (CMRX) | 3.2 | $4.7M | 1.2M | 4.03 | |
Achaogen | 3.0 | $4.5M | 300k | 15.14 | |
Evoke Pharma | 3.0 | $4.4M | 695k | 6.35 | |
Blueprint Medicines (BPMC) | 2.7 | $4.0M | 835k | 4.81 | |
Agios Pharmaceuticals (AGIO) | 2.5 | $3.8M | 1.8M | 2.16 | |
Adaptimmune Therapeutics (ADAP) | 2.4 | $3.6M | 85k | 41.89 | |
Foamix Pharmaceuticals | 2.2 | $3.3M | 200k | 16.47 | |
Ultragenyx Pharmaceutical (RARE) | 2.1 | $3.2M | 65k | 48.91 | |
Medivation | 2.0 | $3.0M | 112k | 26.99 | |
Geron Corporation (GERN) | 2.0 | $3.0M | 1.3M | 2.32 | |
Intec Pharma | 2.0 | $3.0M | 650k | 4.60 | |
Affimed Therapeutics B V | 1.9 | $2.9M | 120k | 23.92 | |
Cara Therapeutics (CARA) | 1.8 | $2.7M | 675k | 3.93 | |
Sage Therapeutics (SAGE) | 1.7 | $2.5M | 125k | 20.37 | |
Fibrogen (FGEN) | 1.7 | $2.5M | 152k | 16.59 | |
Xenon Pharmaceuticals (XENE) | 1.6 | $2.4M | 410k | 5.90 | |
DepoMed | 1.5 | $2.3M | 226k | 10.11 | |
Medgenics | 1.4 | $2.1M | 260k | 8.10 | |
Corium Intl | 1.4 | $2.1M | 125k | 16.75 | |
Ohr Pharmaceutical | 1.4 | $2.0M | 147k | 13.91 | |
Nektar Therapeutics (NKTR) | 1.4 | $2.0M | 270k | 7.50 | |
AMAG Pharmaceuticals | 1.3 | $2.0M | 295k | 6.62 | |
Cytrx | 1.3 | $1.9M | 50k | 38.80 | |
XOMA CORP Common equity shares | 1.3 | $1.9M | 240k | 8.05 | |
Trillium Therapeutics, Inc. Cmn | 1.2 | $1.8M | 195k | 8.98 | |
Retrophin | 1.1 | $1.7M | 58k | 29.04 | |
Cynapsus Therapeutics | 1.1 | $1.6M | 160k | 10.21 | |
Tg Therapeutics (TGTX) | 1.1 | $1.6M | 800k | 1.99 | |
Adamas Pharmaceuticals | 1.0 | $1.5M | 595k | 2.48 | |
Imprimis Pharmaceuticals | 1.0 | $1.5M | 265k | 5.51 | |
Ariad Pharmaceuticals | 0.9 | $1.4M | 340k | 4.19 | |
Nivalis Therapeutics | 0.9 | $1.3M | 260k | 4.95 | |
Protalix Biotherapeutics Inc note 4.500% 9/1 | 0.8 | $1.3M | 105k | 12.13 | |
Codexis (CDXS) | 0.8 | $1.2M | 360k | 3.47 | |
Supernus Pharmaceuticals (SUPN) | 0.8 | $1.2M | 465k | 2.56 | |
Tenax Therapeutics | 0.7 | $1.1M | 175k | 6.06 | |
Eagle Pharmaceuticals (EGRX) | 0.6 | $891k | 130k | 6.85 | |
Neuroderm Ltd F | 0.6 | $853k | 53k | 16.25 | |
Chiasma | 0.3 | $443k | 43k | 10.30 | |
Aclaris Therapeutics (ACRS) | 0.2 | $326k | 40k | 8.15 | |
Axogen (AXGN) | 0.1 | $223k | 250k | 0.89 |